Group 1: Company Overview - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., has a stock code of 301617 and is referred to as Boyuan Co. [1] Group 2: Investor Relations Activity - The investor relations activity involved a specific audience survey and included participants from various financial institutions such as Nuode Fund, Changjiang Securities, and others [2] - The meeting took place on October 31, 2025, in the Boyuan Co. conference room [2] Group 3: Product Capacity and Applications - The company has an existing production capacity of 4,100 tons/year for iodide products, which include inorganic iodides like potassium iodide and sodium iodide, as well as organic iodides such as trimethyl iodide [2][3] - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, with applications in X-ray contrast agents, disinfectants, and LCD/LED screen polarizers [3] Group 4: Strategic Partnerships - Boyuan Co. signed a strategic cooperation framework agreement with Dongsheng Technology in October 2025, focusing on resource integration and technological innovation to enhance competitiveness in the solid-state battery materials industry [2] Group 5: Global Iodine Market Insights - According to SQM's 2024 annual report, the downstream application structure of iodine shows that X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing account for approximately 63% of global consumption [3] - The global iodine production is concentrated in Chile, Japan, and the USA, which together account for 88% of total sales, with Chilean companies alone contributing 60% of global iodine sales [3]
博苑股份(301617) - 2025年10月31日投资者关系活动记录表